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Since the last decade, geriatrics and geron-
tology researchers have been devoting an
increasing amount of efforts in the attempt
of designing, developing, and implement-
ing preventive interventions against con-
ditions determining/driving the disabling
cascade. The urgency of moving ahead in
the field is not merely dictated by scientific
interests; such need has indeed become a
frequent and central item in the agendas of
public health authorities (Guralnik et al.,
1996). In fact, there is a growing demand
for the identification of effective solutions
against the detrimental consequences that
age-related conditions (in particular, dis-
abilities) exert on our healthcare systems.
Special attention has been given to sarcope-
nia (Janssen et al., 2004) and frailty (Clegg
et al., 2013) because both are (1) highly
prevalent in the elderly, (2) associated with
negative health-related events, (3) poten-
tially reversible, and (4) relatively easy to
implement in the clinical practice.
The term “sarcopenia” was coined by
Rosenberg to indicate the loss of muscle
mass that accompanies aging. He clearly
stated that “there is probably no decline in
structure and function more dramatic than
the decline in lean body mass or muscle
mass over the decades of life” (Rosenberg,
1997). The muscle loss was therefore seen
as a means of convenience for exploring the
aging process and its consequences on an
individual’s health. Nevertheless, the skele-
tal muscle cannot be isolated by the hosting
organism. As such, it is still subject to the
influence of all the positive and negative
stressors to which the organism is exposed.
In other words, the endogenous and exoge-
nous phenomena capable of modifying the
aging trajectory of the organism can also
(more or less directly) influence the quality
and quantity of the muscle.
Frailty is the term used to indicate a geri-
atric syndrome characterized by reduced
homeostatic reserves, which exposes the
individual at increased risk of negative
health-related events (including falls, hos-
pitalizations, worsening disability, institu-
tionalization, and mortality) (Rodríguez-
Mañas et al., 2012; Clegg et al., 2013).
Different operational definitions have been
proposed for capturing the frailty status,
each one focusing on specific aspects of the
syndrome and detecting slightly different
risk profiles (Theou et al., 2014). Never-
theless, there is an overall agreement about
the key role that physical function (in par-
ticular, mobility) plays in the determina-
tion of the status of extreme vulnerability
(Ferrucci et al., 2004; Daniels et al., 2008;
Abellan van Kan et al., 2009).
Since the beginning (roughly about 15–
20 years ago), sarcopenia and frailty have
been studied in parallel. Being organ-
specific, sarcopenia was more frequently
object of research in basic science, whereas
the concept of frailty tended to be more
easily applied in the clinical setting (Bauer
and Sieber, 2008). However, it was quite
inevitable that the two would have sooner
or later started converging due to their
close relationship with the aging process.
Unfortunately, the definition of a clear
framework within which sarcopenia and
frailty can be accommodated and stud-
ied has yet to come. One major issue in
this context is the long-lasting, tiring, and
potentially pointless controversy about the
causal relationship existing between the
two. Determining whether frailty is due
to sarcopenia, or sarcopenia is a clinical
manifestation of frailty is consuming con-
siderable efforts, and (from a very practical
viewpoint) rather resembles the problem
of “the egg and the chicken.”
We realize that the clarification of this
point might have major consequences in
the field, determining different risk profiles
to be detected and, consequently, redraw-
ing outcomes as well as interventions to be
adopted. Yet, the isolation of a single patho-
physiological determinant responsible for
these complex conditions (as well as for any
other age-related process) is quite unlikely
to be obtained, simply because aging is
a complicated and still largely unknown
phenomenon (Cesari et al., 2013).
By stating this, we are not surrendering
to the current limitations of science. We
are instead soliciting the taking of more
pragmatic decisions on this topic, waiting
that next-to-come scientific advancements
allow a better clarification and definition
of such urgent and pivotal matters. From
this perspective, deconstructing the inner
foundations of these “twin” conditions and
trying to focus on the shared and clinical
relevant features of them might represent
a possible solution. By this way, we might
have the opportunity to (1) define a unique
target for both sarcopenia and frailty, (2)
simplify their operational definition, and
(3) promote the implementation of the two
conditions in both clinical and research
settings.
As shown in Figure 1, sarcopenia and
frailty are characterized by a unique core
condition: the physical function impair-
ment (usually measured by objective tests
of gait speed and muscle strength). Such
impairment may be responsible for the
concurrent existence of a disability as well
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FIGURE 1 | Relationship among sarcopenia, frailty, and physical function impairment.
as represent a consequence of it. It is indeed
the presence of disability that influences
the framing under which the sarcopenia–
frailty relationship should be observed. In
fact, in the disabled individual, sarcope-
nia and frailty might more likely rep-
resent the consequences of a permanent
disruption of the organism’s homeostasis
with limited chances of reversibility. In
such situation, sarcopenia rather tends to
assume the lineaments of cachexia (Rol-
land et al., 2011), whereas the frailty status
is largely dominated by the disabling con-
dition (Fried et al., 2004). This scenario of
tertiary prevention requires the treatment
of disability plus ancillary interventions
aimed at reducing the risks of complica-
tions (Gordis, 2009). The physical function
impairment resulting from the combina-
tion of sarcopenia and frailty assumes com-
pletely different aspects when detected in
the absence of disability. In this case, it
will represent the first preliminary stage of
a process potentially driving the individ-
ual toward more severe functional losses
and incapacities. In other words, by act-
ing in the preclinical phase of the illness,
it will define an ideal target for activities
of secondary prevention against disability
(Gordis, 2009).
When sarcopenia, frailty, and disabil-
ity are simultaneously present, disentan-
gling one from the others becomes almost
impossible. In fact, the interactions among
sarcopenia, frailty, and disability will take
the shape of a vicious circle character-
ized by the exponential and concurrent
worsening of all the three. Differently,
if disability is absent, the relationship
between sarcopenia and frailty might be
conceptualized as a vector with a pre-
defined direction and for which the only
missing information is its sense. Such miss-
ing datum is not clinically relevant if the
intervention to be put in place is capable
of positively influence both the conditions
of interest at the same time. To put it dif-
ferently, by eliminating one condition (i.e.,
disability) from the framework, the pic-
ture becomes clearer and potentially easier
to address. Not surprisingly, most of the
clinical activities in the field of frailty and
sarcopenia are indeed aimed at prevent-
ing incident disability (Subra et al., 2012;
Maggio et al., 2014).
The shared features that make sar-
copenia and frailty particularly appeal-
ing in the study of age-related conditions
are contended with the common issue
represented by their difficult translation
from theory into practice. The theoret-
ical definitions of sarcopenia and frailty
are both well described and quite unani-
mously accepted. Nevertheless, both con-
cepts currently lack unique, standardized,
and universally agreed operational defin-
itions. Several consensus papers have pro-
vided recommendations on how to identify
sarcopenic individuals (Cruz-Jentoft et al.,
2010; Muscaritoli et al., 2010; Fielding et al.,
2011; Morley et al., 2011). Just recently, in
order to address the existing inconsisten-
cies, a set of articles by the foundation for
the national institutes of health (FNIH) has
been published (Alley et al., 2014; Cawthon
et al., 2014; Dam et al., 2014; McLean et al.,
2014; Studenski et al., 2014). One of the
major features of these recent publications
(besides of being based on ad hoc analyses
of large sample populations) is the attempt
to better discriminate the specific contri-
butions of the skeletal muscle mass and
function in the generation of the negative
outcomes (in particular, mobility disabil-
ity). Similar to sarcopenia, multiple defi-
nitions of frailty have also been developed
over the last years (Clegg et al., 2013; Theou
et al., 2014). Despite the existence of differ-
ent positions in the scientific community
about the concept of frailty and its opera-
tionalization, it is noteworthy the publica-
tion of a recent report by an international
panel of experts (Morley et al., 2013). In the
article, the authors (from different schools
of thought) unanimously convened about
the need of taking a step forward in the
study of frailty, avoiding any further delay,
and promoting the implementation of the
syndrome in clinics and research.
The heterogeneous modalities of
measuring sarcopenia and frailty make
them difficult to be accepted by public
health authorities and regulatory agen-
cies, inevitably endangering advancements
in the field. This issue is particularly
annoying, especially if it is realized that
no assessment tool in medicine will ever be
able to accurately replicate the measured
condition. In fact, the measurement may
be considered as the forcedly limited and
arbitrary mean through which we obtain
an estimate of a specific phenomenon of
the overall health status (mostly unknown
to us in its detailed pathophysiological
characteristics). The speculative aspect
of choosing one operational definition
over another is particularly frustrating in
geriatrics and gerontology where every
condition is watered and confused by
the effects of aging at both clinical and
subclinical levels (Cesari et al., 2013).
By acknowledging such limitations
[which are also responsible for the well
known “evidence-based” issue in geriatric
medicine (Straus and McAlister, 2000;
Scott and Guyatt, 2010)], it becomes rea-
sonable and practical to better pay atten-
tion to what really matters in the sar-
copenic and/or frail older person. If we
isolate the clinical manifestations shared
by both sarcopenia and frailty, we might
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easily agree that physical function is at the
very core of the two (Figure 1). In partic-
ular, mobility (resulting from the proper
functioning of muscles, coordination, and
balance) is a capacity common to almost
every living being (Dickinson et al., 2000).
This implies that animal models focused
on mobility may support the development
of novel interventions against disability by
providing crucial preliminary information
(Carter et al., 2012). Mobility decline is a
clear manifestation of aging and represents
a major negative event of life (Cummings
et al., 2014). It is also noteworthy that phys-
ical function can easily be measured in an
objective way (Studenski et al., 2003), is
predictive of adverse outcomes (Guralnik
et al., 1994, 1995; Studenski et al., 2011),
and represents the clearest (and most obvi-
ous) estimate of skeletal muscle production
(or in a broader sense, quality) (Lauretani
et al., 2003).
Freeing the concepts of sarcopenia and
frailty from what can be perceived as only
indirectly related to the target organ (i.e.,
skeletal muscle) may indeed represent a
possible solution for combining them into
a unique, objective, standardized, and clin-
ically relevant definition (Figure 1). The
implementation in clinical and research
settings might also be significantly facili-
tated by the huge body of literature explor-
ing/describing the condition of physical
impairment and the validity/acceptance of
dedicated instruments [in particular, the
short physical performance battery (Gural-
nik et al., 1994), usual gait speed (Stu-
denski et al., 2011), and handgrip strength
(Rantanen et al., 1999)].
In conclusion, we believe there is an
urgent need of refining the assessments of
sarcopenia and frailty. The physical func-
tion impairment occurring in the absence
of disability may represent the shared core
of the two conditions and optimally serve
for (1) defining a novel target for inter-
ventions against disability, (2) facilitating
the translation of the two conditions in the
clinical arena, and (3) providing an objec-
tive, standardized, and clinically relevant
condition to be adopted by public health
and regulatory agencies. Such conceptu-
alization might eventually encourage key
stakeholders to join their efforts for more
correctly and efficiently approaching the
age-related conditions of sarcopenia and
frailty, two entities that are still not yet
adequately considered.
REFERENCES
Abellan van Kan, G., Rolland, Y., Andrieu, S., Bauer, J.,
Beauchet, O., Bonnefoy, M., et al. (2009). Gait speed
at usual pace as a predictor of adverse outcomes
in community-dwelling older people an interna-
tional academy on nutrition and aging (IANA)
task force. J. Nutr. Health Aging 13, 881–889.
doi:10.1007/s12603-009-0246-z
Alley, D. E., Shardell, M. D., Peters, K. W., McLean,
R. R., Dam, T. T., Kenny, A. M., et al. (2014). Grip
strength cutpoints for the identification of clinically
relevant weakness. J. Gerontol. A Biol. Sci. Med. Sci.
69, 559–566. doi:10.1093/gerona/glu011
Bauer, J. M., and Sieber, C. C. (2008). Sarcopenia
and frailty: a clinician’s controversial point of view.
Exp. Gerontol. 43, 674–678. doi:10.1016/j.exger.
2008.03.007
Carter, C. S., Marzetti, E., Leeuwenburgh, C., Manini,
T., Foster, T. C., Groban, L., et al. (2012). Useful-
ness of preclinical models for assessing the efficacy
of late-life interventions for sarcopenia. J. Gerontol.
A Biol. Sci.Med. Sci. 67, 17–27. doi:10.1093/gerona/
glr042
Cawthon, P. M., Peters, K. W., Shardell, M. D., McLean,
R. R., Dam, T. T., Kenny, A. M., et al. (2014). Cut-
points for low appendicular lean mass that iden-
tify older adults with clinically significant weak-
ness. J. Gerontol. A Biol. Sci. Med. Sci. 69, 567–575.
doi:10.1093/gerona/glu023
Cesari, M., Vellas, B., and Gambassi, G. (2013). The
stress of aging. Exp. Gerontol. 48, 451–456. doi:10.
1016/j.exger.2012.10.004
Clegg, A., Young, J., Iliffe, S., Rikkert, M. O., and
Rockwood, K. (2013). Frailty in elderly people.
Lancet 381, 752–762. doi:10.1016/S0140-6736(12)
62167-9
Cruz-Jentoft, A. J., Baeyens, J. P., Bauer, J. M., Boirie,
Y., Cederholm, T., Landi, F., et al. (2010). Sarcope-
nia: European consensus on definition and diagno-
sis: report of the European working group on sar-
copenia in older people. Age Ageing 39, 412–423.
doi:10.1093/ageing/afq034
Cummings, S. R., Studenski, S., and Ferrucci, L. (2014).
A diagnosis of dismobility-giving mobility clini-
cal visibility: a mobility working group recommen-
dation. JAMA 311, 2061–2062. doi:10.1001/jama.
2014.3033
Dam, T. T., Peters, K. W., Fragala, M., Cawthon, P. M.,
Harris, T. B., McLean, R., et al. (2014). An evidence-
based comparison of operational criteria for the
presence of sarcopenia. J. Gerontol. A Biol. Sci. Med.
Sci. 69, 584–590. doi:10.1093/gerona/glu013
Daniels, R., van Rossum, E., de Witte, L., Kempen, G.
I., and van den Heuvel, W. (2008). Interventions
to prevent disability in frail community-dwelling
elderly: a systematic review. BMC Health Serv. Res.
8:278. doi:10.1186/1472-6963-8-278
Dickinson, M. H., Farley, C. T., Full, R. J., Koehl, M.
A., Kram, R., and Lehman, S. (2000). How animals
move: an integrative view. Science 288, 100–106.
doi:10.1126/science.288.5463.100
Ferrucci, L., Guralnik, J. M., Studenski, S., Fried, L.
P., Cutler, G. B. Jr., Walston, J. D., et al. (2004).
Designing randomized, controlled trials aimed at
preventing or delaying functional decline and dis-
ability in frail, older persons: a consensus report. J.
Am. Geriatr. Soc. 52, 625–634. doi:10.1111/j.1532-
5415.2004.52174.x
Fielding, R. A., Vellas, B., Evans, W. J., Bhasin, S.,
Morley, J. E., Newman, A. B., et al. (2011). Sar-
copenia: an undiagnosed condition in older adults.
Current consensus definition: prevalence, etiology,
and consequences. International working group on
sarcopenia. J. Am. Med. Dir. Assoc. 12, 249–256.
doi:10.1016/j.jamda.2011.01.003
Fried, L. P., Ferrucci, L., Darer, J., Williamson, J. D.,
and Anderson, G. (2004). Untangling the concepts
of disability, frailty, and comorbidity: implications
for improved targeting and care. J. Gerontol. A Biol.
Sci. Med. Sci. 59, 255–263. doi:10.1093/gerona/59.
3.M255
Gordis, L. (2009). “The epidemiologic approach to
disease and intervention,” in Epidemiology, ed. L.
Gordis (Philadelphia, PA: Saunders Elsevier), 1–17.
Guralnik, J. M., Ferrucci, L., Simonsick, E. M., Salive,
M. E., and Wallace, R. B. (1995). Lower-extremity
function in persons over the age of 70 years as a pre-
dictor of subsequent disability. N. Engl. J. Med. 332,
556–561. doi:10.1056/NEJM199503023320902
Guralnik, J. M., Fried, L. P., and Salive, M. E. (1996).
Disability as a public health outcome in the aging
population. Annu. Rev. Public Health 17, 25–46.
doi:10.1146/annurev.pu.17.050196.000325
Guralnik, J. M., Simonsick, E. M., Ferrucci, L., Glynn,
R. J., Berkman, L. F., Blazer, D. G., et al. (1994). A
short physical performance battery assessing lower
extremity function: association with self-reported
disability and prediction of mortality and nurs-
ing home admission. J. Gerontol. 49, M85–M94.
doi:10.1093/geronj/49.2.M85
Janssen, I., Shepard, D. S., Katzmarzyk, P. T., and
Roubenoff, R. (2004). The healthcare costs of sar-
copenia in the United States. J. Am. Geriatr. Soc. 52,
80–85. doi:10.1111/j.1532-5415.2004.52014.x
Lauretani, F., Russo, C. R., Bandinelli, S., Bartali,
B., Cavazzini, C., Di Iorio, A., et al. (2003). Age-
associated changes in skeletal muscles and their
effect on mobility: an operational diagnosis of sar-
copenia. J. Appl. Physiol. 95, 1851–1860. doi:10.
1152/japplphysiol.00246.2003
Maggio, M., Ceda, G. P., and Lauretani, F. (2014). The
multidomain mobility lab in older persons: from
bench to bedside. Curr. Pharm. Des. 20, 3093–3094.
doi:10.2174/138161282019140523115611
McLean, R. R., Shardell, M. D., Alley, D. E., Cawthon,
P. M., Fragala, M. S., Harris, T. B., et al. (2014).
Criteria for clinically relevant weakness and low
lean mass and their longitudinal association
with incident mobility impairment and mortal-
ity: the foundation for the national institutes
of health (FNIH) sarcopenia project. J. Gerontol.
A Biol. Sci. Med. Sci. 69, 576–583. doi:10.1093/
gerona/glu012
Morley, J. E., Abbatecola, A. M., Argiles, J. M., Bara-
cos, V., Bauer, J., Bhasin, S., et al. (2011). Sar-
copenia with limited mobility: an international
consensus. J. Am. Med. Dir. Assoc. 12, 403–409.
doi:10.1016/j.jamda.2011.04.014
Morley, J. E., Vellas, B., van Kan, G. A., Anker, S. D.,
Bauer, J. M., Bernabei, R., et al. (2013). Frailty con-
sensus: a call to action. J. Am. Med. Dir. Assoc. 14,
392–397. doi:10.1016/j.jamda.2013.03.022
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 192 | 3
Cesari et al. Sarcopenia and physical frailty
Muscaritoli, M., Anker, S. D., Argiles, J., Aversa, Z.,
Bauer, J. M., Biolo, G., et al. (2010). Consen-
sus definition of sarcopenia, cachexia and pre-
cachexia: joint document elaborated by special
interest groups (SIG)“cachexia-anorexia in chronic
wasting diseases” and “nutrition in geriatrics”.
Clin. Nutr. 29, 154–159. doi:10.1016/j.clnu.2009.
12.004
Rantanen, T., Guralnik, J. M., Foley, D., Masaki, K., Lev-
eille, S., Curb, J. D., et al. (1999). Midlife hand grip
strength as a predictor of old age disability. JAMA
281, 558–560. doi:10.1001/jama.281.6.558
Rodríguez-Mañas, L., Féart, C., Mann, G., Viña, J.,
Chatterji, S., Chodzko-Zajko, W., et al. (2012).
Searching for an operational definition of frailty:
a Delphi method based consensus statement. The
frailty operative definition-consensus conference
project. J. Gerontol. A Biol. Sci. Med. Sci. 68, 62–67.
doi:10.1093/gerona/gls119
Rolland, Y., Abellan van Kan, G., Gillette-Guyonnet,
S., and Vellas, B. (2011). Cachexia versus sarcope-
nia. Curr. Opin. Clin. Nutr. Metab. Care 14, 15–21.
doi:10.1097/MCO.0b013e328340c2c2
Rosenberg, I. H. (1997). Sarcopenia: origins and clini-
cal relevance. J. Nutr. 127, 990S–991S.
Scott, I. A., and Guyatt, G. H. (2010). Cautionary tales
in the interpretation of clinical studies involving
older persons. Arch. Intern. Med. 170, 587–595.
doi:10.1001/archinternmed.2010.18
Straus, S. E., and McAlister, F. A. (2000). Evidence-
based medicine: a commentary on common criti-
cisms. CMAJ 163, 837–841.
Studenski, S., Perera, S., Patel, K., Rosano, C., Faulkner,
K., Inzitari, M., et al. (2011). Gait speed and sur-
vival in older adults. JAMA 305, 50–58. doi:10.
1001/jama.2010.1923
Studenski, S., Perera, S., Wallace, D., Chandler, J. M.,
Duncan, P. W., Rooney, E., et al. (2003). Physical
performance measures in the clinical setting. J. Am.
Geriatr. Soc. 51, 314–322. doi:10.1046/j.1532-5415.
2003.51104.x
Studenski, S. A., Peters, K. W., Alley, D. E., Cawthon, P.
M., McLean, R. R., Harris, T. B., et al. (2014). The
FNIH sarcopenia project: rationale, study descrip-
tion, conference recommendations, and final esti-
mates. J. Gerontol. A Biol. Sci.Med. Sci. 69, 547–558.
doi:10.1093/gerona/glu010
Subra, J., Gillette-Guyonnet, S., Cesari, M., Oustric,
S., and Vellas, B. (2012). The integration of frailty
into clinical practice: preliminary results from the
gérontopôle. J. Nutr. Health Aging 16, 714–720.
doi:10.1007/s12603-012-0391-7
Theou, O., Brothers, T. D., Pena, F. G., Mitnitski, A.,
and Rockwood, K. (2014). Identifying common
characteristics of frailty across seven scales. J. Am.
Geriatr. Soc. 62, 901–906. doi:10.1111/jgs.12773
Conflict of Interest Statement: The authors declare
that the research was conducted in the absence of any
commercial or financial relationships that could be
construed as a potential conflict of interest.
Received: 06 June 2014; paper pending published: 26 June
2014; accepted: 12 July 2014; published online: 28 July
2014.
Citation: Cesari M, Landi F, Vellas B, Bernabei R and
Marzetti E (2014) Sarcopenia and physical frailty: two
sides of the same coin. Front. Aging Neurosci. 6:192. doi:
10.3389/fnagi.2014.00192
This article was submitted to the journal Frontiers in
Aging Neuroscience.
Copyright © 2014 Cesari, Landi, Vellas, Bernabei and
Marzetti. This is an open-access article distributed under
the terms of the Creative Commons Attribution License
(CC BY). The use, distribution or reproduction in other
forums is permitted, provided the original author(s) or
licensor are credited and that the original publication in
this journal is cited, in accordance with accepted aca-
demic practice. No use, distribution or reproduction is
permitted which does not comply with these terms.
Frontiers in Aging Neuroscience www.frontiersin.org July 2014 | Volume 6 | Article 192 | 4
